Does Longitudinal Nursing Follow-up Improve Smoking Cessation in Patients Referred for COPD Screening (BPCO)

March 17, 2026 updated by: Centre Hospitalier de Valence

Does Longitudinal Nursing Follow-up Improve Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Screening

a monocentric study to evaluate the efficacy of a longitudinal nursing follow up in smoking cessation in patients screened for Chronic obstructive pulmonary disease (COPD).

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

The challenges to limit the occurrence of COPD are early detection, the fight against smoking and smoking and addictions (e.g. Cannabis), as well as the fight against environmental exposures.

we proposed to evaluate if a longitudinal nursing follow-up at 3 months, 6 months and one year, in patients coming to screening for COPD.

Cessation of respiratory toxics is the most effective intervention in stopping the progression of COPD.

Study Type

Observational

Enrollment (Estimated)

233

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Drome
      • Valence, Drome, France, 26953
        • CH Valence

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Smoking patients screened for COPD between 35 years old 65 years old

Description

Inclusion Criteria:

  • Smoking patients screened for COPD between 35 years old 65 years old
  • Read, write and understand the French language
  • Patient affiliated to a social security system
  • Written and signed informed consent

Exclusion Criteria:

  • Patients with a diagnosis of respiratory diseases
  • Patients receiving inhaled respiratory therapy
  • Persons unable to perform spirometry
  • Pregnant women
  • Refusal to participate in research
  • Patient under guardianship, deprived of liberty, safeguard of justice

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of cigarettes or other toxic substances
Time Frame: up to 1 year
per day
up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier de Valence

Investigators

  • Principal Investigator: Gilles RIVAL, MD, CH Valence

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2020

Primary Completion (Estimated)

September 11, 2026

Study Completion (Estimated)

September 11, 2026

Study Registration Dates

First Submitted

October 10, 2022

First Submitted That Met QC Criteria

October 10, 2022

First Posted (Actual)

October 13, 2022

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RIPH-CHV-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe